Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials

BACKGROUND: Anti-programmed cell death protein 1 (PD-1) antibodies have demonstrated significant clinical activity in many cancer entities. Gastrointestinal toxicities are one of its major side effects, but the overall risks have not been systematically evaluated. Thus, the purpose of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wei, Luo, Zhibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728786/
https://www.ncbi.nlm.nih.gov/pubmed/29310385
http://dx.doi.org/10.1097/MD.0000000000008931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728786/
https://www.ncbi.nlm.nih.gov/pubmed/29310385
http://dx.doi.org/10.1097/MD.0000000000008931

Ejemplares similares